Atlas Trials

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Clinical trial NCT02118987 · COMPLETED

Trial details

NCT number
NCT02118987
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Drug Allergy
Start date
2014-07-01
Primary completion
2017-12-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.